Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. Viridian’s goal is to advance VRDN-001 as a potential best-in-class intravenous therapy followed by VRDN-003 as a potential first- and best-in-class subcutaneous therapy for the treatment of TED.
In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Company Details
- Employees
- 224
- Founded
- -
- Address
- 203 Crescent St, Building 17,suite 102b,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Waltham, Massachusetts
Viridian Therapeutics, Inc. Questions
Viridian Therapeutics, Inc.'s website is http://www.viridiantherapeutics.com
Viridian Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/viridiantx
Viridian Therapeutics, Inc. has
224 employees.
View email and phone details for 224
employees at Viridian Therapeutics, Inc..
Viridian Therapeutics, Inc.'s industry is
Biotechnology Research
Viridian Therapeutics, Inc.'s top competitors are
Oruka Therapeutics,
Zenas Biopharma,
Summit Therapeutics, Inc.,
Astria Therapeutics, Inc.,
Ionis Pharmaceuticals, Inc.,
Candid Therapeutics,
Dianthus Therapeutics, Inc.,
Centessa Pharmaceuticals,
Mbx Biosciences, Inc.,
Bicara Therapeutics.
Viridian Therapeutics, Inc.'s categories are Biotechnology Research
Viridian Therapeutics, Inc.'s founding year is 2007
